Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669407 | 0.81 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL9406736 | 0.75 | PI4KA (0.54) | EGLN1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6270795 | 0.74 | DPP4 (0.40) | — | |
| SCHEMBL9406669 | 0.73 | PI4KA (0.62) | EGLN1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7359070 | 0.72 | PRMT5 (0.47) | LMNATSHR | |
| SCHEMBL6016629 | 0.71 | EGLN1 (0.43) | EGLN1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1079071 | 0.69 | METAP2 (0.41) | — | |
| SCHEMBL10910539 | 0.68 | ADORA2A (0.61) | EGLN1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1868817 | 0.68 | ADORA2A (0.43) | EGLN1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1350377 | 0.67 | ALDH1A1 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | BENKOVIC STEPHEN J | 2005-10-13 | — | — | US | disclosed |
| US-20040259833-A1 | DNA methyl transferase inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| EP-1420021-A1 | DNA Methyltransferase inhibitors | The Penn State Research Foundation (US) | 2004-05-19 | — | — | EP | disclosed |
| CN-1370170-A | DNA methyltransferase inhibitors | PENN STATE RES FOUND (US) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | DNMT1, TPMT, GNMT | EGLN1 1541/4885PI4KA 3118/4885PI4K2B 3428/4885 |
| US-20040259833-A1 | DNA methyl transferase inhibitors | DNMT1, DNMT3A, DIMT1 | EGLN1 3048/4885PI4KA 2170/4885PI4K2B 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.